4.7 Article

Potentiality of raloxifene loaded melittin functionalized lipidic nanovesicles against pancreatic cancer cells

期刊

DRUG DELIVERY
卷 29, 期 1, 页码 1863-1877

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1080/10717544.2022.2072544

关键词

Liposomes; ultrasonication; PANC1; apoptosis; membrane potential

资金

  1. Deanship of Scientific Research (DSR) at King Abdulaziz University, Jeddah [RG-13-166-42]

向作者/读者索取更多资源

Pancreatic cancer has seen a rapid increase in frequency and incidence in recent years. The main challenges with pancreatic cancer include the lack of early detection due to asymptomatic manifestations and the scarcity of well-defined pharmacotherapeutic drugs. This study aimed to develop an efficient nanocarrier system to enhance the effectiveness of raloxifene against pancreatic cancer cells. The results showed that the optimized nanovesicle formulation exhibited improved anti-pancreatic cancer effects.
Pancreatic cancer (PC) frequency and incidence have grown rapidly in recent years. One of the most serious problems with PC is the existence of asymptotic manifestations, which frequently delays early detection, and until the diagnosis is established, tumor cells progress to the metastatic stage. Another significant concern with PC is the scarcity of well-defined pharmacotherapeutic drugs. The aim of this study was to develop an efficient nanocarrier system to augment the efficacy of raloxifene (RLX) against PC cells. As a result, the current investigation was carried out in order to give an effective treatment method, in which an optimum RLX loaded phospholipid-based vesicles with melittin (PL-MEL) was chosen using experimental design software, with particle size, zeta potential and entrapment efficiency % as dependent variables. Furthermore, anticancer activity against PANC1 cells was assessed. The optimized nanovesicle parameters were 172.5 nm for the measured size, zeta potential of -0.69 mV, and entrapment efficiency of 76.91% that were in good agreement with the expected ones. RLX-raw, plain formula, and optimized RLX-PL-MEL showed IC50 concentrations of 26.07 +/- 0.98, 9.166 +/- 0.34, and 1.24 +/- 0.05 mu g/mL, respectively. Furthermore, cell cycle analysis revealed that the nanovesicle was most effective in the G2-M phase, whereas Bax, and Bcl-2 estimates revealed that optimized RLX formula had the highest apoptotic activity among treatments investigated. However, as compared to RLX alone or plain formula alone, the optimized formula demonstrated higher expression of TNF alpha and Bax while a significant reduction of Bcl-2 and NF-kappa B expression was observed. mitochondrial membrane potential (MMP) analysis confirmed the apoptosis as well as the anticancer effect of the optimized formula. Thus, the present study results showed an improvement in the anti-PC effects of the RLX with phospholipid conjugated melittin, making it a novel treatment approach against PC.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据